Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Anika Therapeutics (ANIK)

Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Anika Therapeutics 32 WIGGINS AVENUE BEDFORD MA 01730 USA

www.anikatherapeutics.com P: 781-457-9000 F: 781-305-9720

Description:

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Key Statistics

Overview:

Market Capitalization, $K 377,636
Enterprise Value, $K 304,766
Shares Outstanding, K 14,850
Annual Sales, $ 166,660 K
Annual Net Income, $ -82,670 K
Last Quarter Sales, $ 42,970 K
Last Quarter Net Income, $ -63,000 K
EBIT, $ -25,440 K
EBITDA, $ 50,970 K
60-Month Beta 0.76
% of Insider Shareholders 5.85%
% of Institutional Shareholders 91.53%
Float, K 13,981
% Float 94.15%
Short Volume Ratio 0.42

Growth:

1-Year Return -6.40%
3-Year Return -38.75%
5-Year Return -23.26%
5-Year Revenue Growth 57.88%
5-Year Earnings Growth -116.30%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -4.30 on 03/13/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -0.37
EPS Growth vs. Prev Year 123.81%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ANIK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 22.78
Price/Earnings to Growth 2.28
Return-on-Equity % -2.10%
Return-on-Assets % -1.71%
Profit Margin % -49.60%
Debt/Equity 0.00
Price/Sales 2.29
Price/Cash Flow 5.18
Price/Book 1.76
Book Value/Share 14.50
Interest Coverage -0.46
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar